Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| | 10-K | 10-K | 10-K | 8-K | S-1/A |
| Revenues: |
| Cardiovascular | 7.3 | 7.5 | | | |
| Device Protection | 9.1 | 7.9 | | | |
| Women's Health | 7.5 | 5.0 | | | |
| Orthobiologics | 25.3 | 26.9 | | | |
| Total revenues | 49.2 | 47.4 | 42.7 | 42.9 | |
| Revenue growth [+] | 3.8% | 11.0% | -0.5% | | |
| Cardiovascular | -3.0% | | | | |
| Device Protection | 15.1% | | | | |
| Women's Health | 48.1% | | | | |
| Orthobiologics | -5.9% | | | | |
| Cost of goods sold | 30.0 | 28.4 | 22.1 | 23.1 | |
| Gross profit | 19.2 | 19.0 | 20.6 | 19.8 | |
| Gross margin | 39.1% | 40.1% | 48.2% | 46.1% | |
| Selling, general and administrative [+] | 36.8 | 32.5 | 28.2 | 25.8 | |
| Sales and marketing | 20.2 | 18.8 | 17.6 | 16.2 | |
| General and administrative | 16.6 | 13.7 | 10.6 | 9.6 | |
| Research and development | 8.9 | 9.3 | 6.0 | 2.4 | |
| EBITDA [+] | -22.8 | -19.0 | -9.7 | | |
| EBITDA growth | 19.9% | 95.4% | 15.8% | | |
| EBITDA margin | -46.4% | -40.1% | -22.8% | -19.6% | |
| Depreciation | 0.3 | 0.3 | 0.5 | | |
| EBITA | -23.1 | -19.4 | -10.2 | -8.4 | |
| EBITA margin | -47.1% | -40.9% | -23.9% | -19.6% | |
| Amortization of intangibles | 3.4 | 3.4 | 3.4 | | |
| EBIT [+] | -26.5 | -22.8 | -13.6 | -8.4 | |
| EBIT growth | 16.6% | 67.3% | 61.7% | | |
| EBIT margin | -54.0% | -48.0% | -31.9% | -19.6% | |
| Non-recurring items [+] | 5.2 | 0.3 | | | |
| Legal settlement | 5.2 | 0.3 | | | |
| Interest expense | 5.3 | 5.3 | 5.6 | | |
| Interest expense | 5.3 | 5.3 | 5.6 | | |
| Other income (expense), net | 4.2 | 3.6 | -2.6 | -3.5 | |
| Pre-tax income | -32.9 | -24.8 | -21.8 | -11.9 | |
| Income taxes | 0.0 | 0.1 | 0.0 | 0.0 | |
| Net income | -32.9 | -24.8 | -25.3 | 0.0 | |
| Net margin | -66.9% | -52.4% | -59.4% | 0.0% | |
| |
| Basic EPS [+] | ($2.38) | ($2.38) | ($8.88) | ($18.48) | |
| Growth | 0.0% | -73.2% | -51.9% | | |
| Diluted EPS [+] | ($2.38) | ($2.38) | ($8.88) | ($18.48) | |
| Growth | 0.0% | -73.2% | -51.9% | | |
| |
| Shares outstanding (basic) [+] | 13.8 | 10.4 | 2.9 | 0.0 | |
| Growth | 32.4% | 266.2% | 441473.9% | | |
| Shares outstanding (diluted) [+] | 13.8 | 10.4 | 2.9 | 0.0 | |
| Growth | 32.4% | 266.2% | 441473.9% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|